Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomivosertib in hematological malignancies
NCT02937675Phase 2Terminated
- Sponsor
- eFFECTOR Therapeutics
- Start
- Feb 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tomivosertib in lymphoma (2 cohorts), sponsored by eFFECTOR Therapeutics. Primary endpoints: Maximum Tolerated Dose and/or Recommended Dose up to 1 year and Overall Response Rate up to 3 years. Started Feb 2017; status: terminated.
02
Drugs
tomivosertib
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT02937675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937675.